RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Has this study been replicated?
The atlas records 1 replication of this study. Recorded outcomes: 1 mixed. The earliest on record is from 2021.
Replications
- Replication Study: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Pelech et al. (2021). bioRxiv (Cold Spring Harbor Laboratory). Outcome recorded: mixed.
To summarize, for this experiment we found results that were not in the same direction as the original study and not statistically significant where predicted.
Outcome read from the results. View paper
Cite this record
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., Morales, T., Aliagas, I., Liu, B., Sideris, S., Hoeflich, K. P., Jaiswal, B. S., Seshagiri, S., Koeppen, H., Belvin, M., … Malek, S. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 464(7287), 431–435. https://doi.org/10.1038/nature08833
Other studies in the atlas
Failed replications · Successful replications · All browse pages